HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cutaneous leishmaniasis — Clinical Guidelines

Overview

Cutaneous leishmaniasis (CL) is a parasitic skin disease caused by Leishmania species, leading to skin ulcers and significant morbidity, particularly in endemic regions 1 2 3 4.

Diagnosis

Clinical Appearance: Diagnosis often relies on characteristic skin lesions, typically ulcers 2 3.

Laboratory Tests:

- Parasitological Smears: Essential for confirming diagnosis 2 3. - Histopathology: Useful when smears are negative, often supporting clinical diagnosis 2.

Response to Therapy: Good therapeutic response can validate clinical diagnosis 2.

Management

First-Line Treatment:

- Intralesional Meglumine Antimoniate: Effective in pediatric cases 3. - Systemic Treatments: Not specified in abstracts, but common alternatives include oral antimonials, amphotericin B, or miltefosine 4.

Adjunctive Measures: Tele-dermatology can enhance access to care in remote areas 1.

Special Populations

Pediatrics: Intralesional meglumine antimoniate is effective with favorable outcomes 3.

Comorbidities: No specific recommendations provided; however, patients with atopic eczema may present atypical lesions 5.

Key Recommendations

Utilize clinical diagnosis by dermatologists as highly accurate (96%) in endemic regions, especially when supported by therapeutic response 2 (Evidence: Strong).

Employ intralesional meglumine antimoniate for pediatric cases of CL, given its efficacy and favorable outcomes 3 (Evidence: Moderate).

Leverage tele-dermatology to improve access to specialized care in remote or underserved areas 1 (Evidence: Weak).

References

1 Parajuli N, Prajapati B. Use of mobile tele-dermatology in managing cutaneous leishmaniasis from a remote district of Nepal during the COVID 19 pandemic: A case series. Tropical doctor 2023. link 2 Ranawaka RR, Abeygunasekara PH, Weerakoon HS. Correlation of clinical, parasitological and histopathological diagnosis of cutaneous leishmaniasis in an endemic region in Sri Lanka. The Ceylon medical journal 2012. link 3 Qasmi S, Elguelbazouri N, Belgnaoui FZ, Marcil T, Bouhllab J, Senouci K et al.. Childhood cutaneous leishmaniasis: Experience of a Moroccan unit of dermatology. Dermatology online journal 2008. link 4 Sarantopoulos GP, Binder S, Wortmann G, Hochberg L, Healey P. Old world cutaneous leishmaniasis in Los Angeles: a case report, overview of the current literature, and guide for the treating dermatopathologist. The American Journal of dermatopathology 2003. link 5 Kubeyinje EP, Belagavi CS. Cutaneous leishmaniasis occurring with atopic eczema: report of three cases. East African medical journal 2000. link

Cutaneous leishmaniasis